This Phase IIb trial compares the active ingredients in NP-1 against
placebo in patients suffering from diabetic peripheral neuropathy (DPN),
the most common form of neuropathic pain. Only two medications are
currently available in the United States for the treatment of DPN. The
four-week, 200- patient trial is intended to confirm and expand upon
earlier work that provided a preliminary efficacy signal in this type of
neuropathic pain. The primary endpoint for the Phase IIb trial is the
difference between active and placebo changes in pain intensity from
baseline compared to the average over the last seven days of treatment.

"We are pleased to have reached another key clinical milestone that we
established for 2007, and to have advanced another one of our product
candidates," stated Jack Talley, President and Chief Executive Officer of
EpiCept. "We believe NP-1 holds the largest market potential of the pain
candidates in our portfolio. Treatment of neuropathic pain is a billion
dollar opportunity. We believe that NP-1 has the potential to become a new
and efficacious topical treatment without the inherent systemic side
effects of alternative treatments for the 15 million Americans who suffer
from peripheral neuropathies. We expect to report top-line results from
this trial in early 2008."

In addition to the NP-1 trial in DPN, there are two other clinical
trials for NP-1 currently underway.

-- A Phase IIb trial is underway in peripheral herpetic neuropathy. This

500-patient, placebo- and active-controlled trial will compare the

efficacy and safety of NP-1 vs. gabapentin and placebo. The primary

endpoint for this trial is the change in pain intensity over the four-

week duration of the trial. Preliminary results are expected early in

the second quarter of 2008.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer.
The Company's broad portfolio of pharmaceutical product candidates includes
several pain therapies in clinical development and a lead oncology compound
for AML with demonstrated efficacy in a Phase III trial; a marketing
authorization application for this compound is approaching a decision in
Europe. In addition, EpiCept's ASAP technology, a proprietary live cell
high- throughput caspase-3 screening technology, can efficiently identify
new cancer drug candidates and molecular targets that selectively induce
apoptosis in cancer cells. Two oncology drug candidates currently in
clinical development that were discovered using this technology have also
been shown to act as vascular disruption agents in a variety of solid
tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include statements which
express plans, anticipation, intent, contingency, goals, targets, future
development and are otherwise not statements of historical fact. These
statements are based on EpiCept's current expectations and are subject to
risks and uncertainties that could cause actual results or developments to
be materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Factors that may
cause actual results or developments to differ materially include: the risk
that our NP-1 clinical trials will not be successful, that NP-1 will not
receive regulatory approval or achieve significant commercial success, the
risk that Ceplene will not receive regulatory approval or marketing
authorization in the EU or that Ceplene, if approved, will not achieve
significant commercial success, the risk that Myriad's development of
Azixa(TM) will not be successful, the risk that Azixa will not receive
regulatory approval or achieve significant commercial success, the risk
that we will not receive any significant payments under our agreement with
Myriad, the risk that the development of our other apoptosis product
candidates will not be successful, the risk that our ASAP technology will
not yield any successful product candidates, the risk that clinical trials
for EPC 2407 will not be successful, that EPC 2407 will not receive
regulatory approval or achieve significant commercial success, the risk
that our other product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept will not
obtain approval to market any of its product candidates, the risks
associated with our need to raise additional financing to continue to meet
our capital needs and our ability to continue as a going concern, the risks
associated with dependence upon key personnel, the risks associated with
reliance on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product candidates;
the cost, delays and uncertainties associated with our scientific research,
product development, clinical trials and regulatory approval process; our
history of operating losses since our inception; competition; litigation;
risks associated with prior material weaknesses in our internal controls;
and risks associated with our ability to protect our intellectual property.
These factors and other material risks are more fully discussed in
EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and
10-K and other filings with the U.S. Securities and Exchange Commission.
You are urged to carefully review and consider the disclosures found in
EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.

(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...

(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...

(Date:12/8/2016)... -- Australia Ophthalmic Lasers Market Outlook to 2022 ... Outlook to 2022", provides key market data on the ... millions of US dollars, volume (in units) and average ... Lasers and YAG Lasers. The report also provides ... these market segements, and global corporate-level profiles of the ...

(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...

(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced the ... to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies in ... Canada , Japan , Europe , ... of World. Annual estimates and forecasts are provided for the period ...